PFE.HM - Pfizer Inc

Hamburg - Hamburg Delayed Price. Currency in EUR
+1.10 (+3.18%)
At close: 11:05AM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close34.55
Bid35.35 x 0
Ask35.40 x 0
Day's Range35.60 - 35.85
52 Week Range33.85 - 52.50
Avg. Volume267
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateJul 26, 2023 - Jul 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PFE.HM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Investor's Business Daily

      Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

      Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

    • Zacks

      Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates

      At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

    • Reuters

      UPDATE 2-Pfizer says its experimental antibiotic combo can treat some superbug infections

      Pfizer Inc said on Thursday data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia.

    • Insider Monkey

      15 Best Healthcare Stocks To Buy Now

      In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]

    • Business Wire

      Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

      NEW YORK, June 01, 2023--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatme

    • Motley Fool

      Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now

      Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.

    • Zacks

      Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval

      The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.

    • The Wall Street Journal

      New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy

      The shot won FDA approval as a new study finds a 14-percentage-point drop in vaccine confidence since the Covid pandemic.

    • Reuters

      UPDATE 2-US FDA approves Pfizer's RSV vaccine

      The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.

    • Business Wire

      U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

      NEW YORK, May 31, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

    • Motley Fool

      Why Pfizer Stock Is Perking Up Today

      Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. Earlier Wednesday, The Wall Street Journal published a column questioning whether investors have turned too bearish on COVID-19 vaccine-makers like Pfizer. Pfizer's shares have fallen by as much as 30% this year in response to the anticipated drop in sales for its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid.

    • Zacks

      Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

      Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

    • Motley Fool

      Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?

      A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.

    • The Wall Street Journal

      Heard on the Street: Investors Are Too Bearish on Vaccine-Makers

      OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](, [Pfizer]( and [BioNTech](https://www.

    • The Wall Street Journal

      Vaccine Fatigue Can Give Your Portfolio a Booster

      Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.

    • Motley Fool

      2 Ultra-Safe Dividend Stocks to Load Up On Right Now

      Which top-shelf dividend stocks are worth buying right now? Allstate (NYSE: ALL) and Pfizer (NYSE: PFE) are two near-locks to produce healthy levels of capital appreciation over the next five to 10 years. Allstate's 2023 Q1 earnings report isn't exactly a confidence-inspiring read.

    • Investor's Business Daily

      Pfizer's Approach To Hemophilia Is 'Certainty Differentiated' — Here's Why Shares Fell

      Pfizer said Tuesday its experimental hemophilia treatment cut down on bleeding episodes in a pivotal study. But Pfizer stock dipped.

    • Zacks

      Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

      The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

    • Zacks

      Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

      Pfizer (PFE) has received quite a bit of attention from users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

    • Reuters

      Pfizer's hemophilia therapy reduces bleeding in late-stage study

      U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients. The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said. Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.

    • Business Wire

      Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

      NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl

    • Motley Fool

      Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

      The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?

    • Zacks

      EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

      Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

    • Motley Fool

      The Top Healthcare Stocks to Buy With $100

      The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.